Peptides for acne and PCOS: what the evidence actually supports

What did @dra.mondillo actually say?

Honestly? It is impossible to tell. The transcript provided for this video is incoherent, containing fragments about rappers, Africa, Atlantic principles, and training sessions that have no apparent connection to acne, hirsutism, or PCOS, which are the topics named in the caption and hashtags. No direct quotes about hormones, peptides, or skin conditions can be pulled from this transcript because none exist in legible form.

The video's caption, hashtags, and category context suggest the creator, identified as an endocrinologist or gynecologist, intended to address the hormonal roots of acne and possibly conditions like polycystic ovary syndrome. That framing is clinically relevant. But what was actually captured in the transcript reviewed here cannot be verified, quoted, or evaluated on its scientific merits. This fact-check will assess what is known about the topic this video appears to address, while being clear that the specific claims made on camera were not recoverable.

Does the science back up the apparent topic?

The connection between PCOS, elevated androgens, and acne is well-established. What is less certain is how far some clinicians push hormonal and peptide-based interventions beyond current evidence.

Hyperandrogenism, the excess of androgens like testosterone and DHEA-S, is a recognized driver of sebaceous gland activity and acne in people with PCOS. A 2020 meta-analysis by Lim et al. in the Journal of the American Academy of Dermatology confirmed that anti-androgen therapies significantly reduced acne severity in women with hormonal acne. Spironolactone remains the most studied oral anti-androgen for this indication in the US.

Where things get murkier is in the peptide category assigned to this video. Peptides like GHK-Cu have been studied for wound healing and some skin remodeling effects, but the evidence connecting peptide therapies specifically to hormonal acne or PCOS management is thin. A 2015 review by Pickart and Margolina in the journal Biomolecules covered GHK-Cu's anti-inflammatory properties, but did not establish clinical efficacy for acne in PCOS populations. The leap from lab findings to TikTok recommendations is one that should be made carefully, if at all.

What did they get wrong (or right)?

Because the transcript is uninterpretable, it is not possible to fairly credit or criticize the specific statements made. That matters, and it is worth saying plainly: fact-checking a video requires the actual claims, not category assumptions.

What can be said is that the framing of acne as an endocrine issue, which the hashtags strongly imply, is medically sound. Dermatologists and gynecologists increasingly co-manage hormonal acne, particularly in patients with confirmed PCOS, and that interdisciplinary framing is appropriate. The hashtags reference endocrinology, gynecology, and dermatology together, which reflects real clinical practice.

However, the peptide category tag on this content raises a flag worth noting. Applying peptide therapy framing to hormonal acne management in PCOS is not standard of care. If the video advocated peptide use as a primary or equivalent treatment to established hormonal therapies like oral contraceptives or spironolactone, that would be a significant overstep of current evidence.

What should you actually know?

Hormonal acne, especially in PCOS, is a real and treatable condition, but the treatment hierarchy matters. Lifestyle, evidence-based medications, and proper hormonal workup come before experimental peptide protocols.

If you have acne alongside irregular periods, excess hair growth, or weight changes, getting a hormonal panel including testosterone, DHEA-S, LH, and FSH is a reasonable first step. A 2018 Endocrine Society clinical practice guideline recommends combined oral contraceptives as first-line therapy for PCOS-related skin and hair symptoms in people who do not want to conceive.

Peptides marketed for skin health are not a replacement for this pathway. Some, like GHK-Cu in topical formulations, have a reasonable safety profile and modest supporting data for skin quality. Others, particularly injectable peptides promoted outside regulated clinical settings, carry unknown risks and no established efficacy for PCOS-related acne specifically. No peptide has regulatory approval for treating acne or hormonal conditions. Anyone suggesting otherwise is outpacing the evidence.

• Get a proper hormonal workup before assuming your acne is PCOS-related.
• Anti-androgen medications have the strongest evidence base for hormonal acne.
• Peptide therapies for acne in PCOS remain largely unproven in clinical trials.
• Telehealth providers prescribing peptides for this indication should be able to cite specific trial data, not general anti-inflammatory mechanisms.